JP2017534618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534618A5 JP2017534618A5 JP2017521988A JP2017521988A JP2017534618A5 JP 2017534618 A5 JP2017534618 A5 JP 2017534618A5 JP 2017521988 A JP2017521988 A JP 2017521988A JP 2017521988 A JP2017521988 A JP 2017521988A JP 2017534618 A5 JP2017534618 A5 JP 2017534618A5
- Authority
- JP
- Japan
- Prior art keywords
- criteria
- sirs
- terlipressin
- treatment
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019155678A JP6989571B2 (ja) | 2014-10-24 | 2019-08-28 | １型肝腎症候群患者の治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068357P | 2014-10-24 | 2014-10-24 | |
| US62/068,357 | 2014-10-24 | ||
| US201562151384P | 2015-04-22 | 2015-04-22 | |
| US62/151,384 | 2015-04-22 | ||
| PCT/US2015/056861 WO2016065117A1 (en) | 2014-10-24 | 2015-10-22 | Method of treating patients with hepatorenal syndrome type 1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019155678A Division JP6989571B2 (ja) | 2014-10-24 | 2019-08-28 | １型肝腎症候群患者の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534618A JP2017534618A (ja) | 2017-11-24 |
| JP2017534618A5 true JP2017534618A5 (enExample) | 2018-09-27 |
| JP6673915B2 JP6673915B2 (ja) | 2020-03-25 |
Family
ID=54478246
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017521988A Active JP6673915B2 (ja) | 2014-10-24 | 2015-10-22 | １型肝腎症候群患者の治療方法 |
| JP2019155678A Active JP6989571B2 (ja) | 2014-10-24 | 2019-08-28 | １型肝腎症候群患者の治療方法 |
| JP2021102221A Active JP7346494B2 (ja) | 2014-10-24 | 2021-06-21 | １型肝腎症候群患者の治療方法 |
| JP2022146052A Withdrawn JP2022171795A (ja) | 2014-10-24 | 2022-09-14 | １型肝腎症候群患者の治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019155678A Active JP6989571B2 (ja) | 2014-10-24 | 2019-08-28 | １型肝腎症候群患者の治療方法 |
| JP2021102221A Active JP7346494B2 (ja) | 2014-10-24 | 2021-06-21 | １型肝腎症候群患者の治療方法 |
| JP2022146052A Withdrawn JP2022171795A (ja) | 2014-10-24 | 2022-09-14 | １型肝腎症候群患者の治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10335452B2 (enExample) |
| EP (3) | EP3981420A1 (enExample) |
| JP (4) | JP6673915B2 (enExample) |
| CN (2) | CN114028536B (enExample) |
| AU (1) | AU2015335855A1 (enExample) |
| CA (1) | CA2965325A1 (enExample) |
| DK (2) | DK3209317T3 (enExample) |
| ES (2) | ES2987577T3 (enExample) |
| FI (1) | FI3978074T3 (enExample) |
| HR (1) | HRP20220225T1 (enExample) |
| HU (1) | HUE058066T2 (enExample) |
| PL (2) | PL3978074T3 (enExample) |
| PT (2) | PT3978074T (enExample) |
| SI (1) | SI3209317T1 (enExample) |
| WO (1) | WO2016065117A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ591810A (en) | 2008-09-17 | 2012-12-21 | Chiasma Inc | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid |
| US20210290725A1 (en) * | 2014-10-24 | 2021-09-23 | Mallinckrodt Pharmaceuticals Ireland Limited | Method of treating patients with hepatorenal syndrome type 1 |
| US20200046798A1 (en) * | 2014-10-24 | 2020-02-13 | Mallinckrodt Hospital Products IP Limited | Method of treating patients with hepatorenal syndrome type 1 |
| HRP20220225T1 (hr) * | 2014-10-24 | 2022-04-29 | Mallinckrodt Pharmaceuticals Ireland Limited | Terlipresin za liječenje hepatorenalnog sindroma tip 1 |
| IL265761B2 (en) * | 2016-10-21 | 2024-11-01 | Amryt Endo Inc | Oral terlipressin compositions for use in treatment of ascites |
| CN114096267B (zh) | 2019-05-22 | 2025-03-18 | 柏欧韦股份有限公司 | 特利加压素制剂 |
| CN110251469B (zh) * | 2019-07-31 | 2021-11-09 | 南京康舟医药科技有限公司 | 一种醋酸特利加压素制剂及其制备方法 |
| CA3159575A1 (en) * | 2019-10-30 | 2021-05-06 | Mallinckrodt Hospital Products IP Unlimited Company | Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure |
| WO2023183339A1 (en) * | 2022-03-22 | 2023-09-28 | Ocelot Bio, Inc. | Selective vasopressin receptor agonist for end-stage liver disease |
| US20240156895A1 (en) * | 2022-10-28 | 2024-05-16 | Mallinckrodt Pharmaceuticals Ireland Limited | Compositions for improving kidney function in patients with hepatorenal syndrome |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1188443A1 (en) | 2000-09-15 | 2002-03-20 | Ferring BV | Improved protocol for paracentesis |
| US7785857B2 (en) * | 2006-08-31 | 2010-08-31 | Saint Louis University | Protein C variant |
| GB0617581D0 (en) * | 2006-09-07 | 2006-10-18 | Ucl Business Plc | Biomarkers for assessing liver function |
| US20080221551A1 (en) * | 2007-03-09 | 2008-09-11 | Flowmedica, Inc. | Acute kidney injury treatment systems and methods |
| WO2009037586A2 (en) | 2007-08-14 | 2009-03-26 | Ferring B.V. | Use of peptidic vasopressin receptor agonists |
| BRPI0922021A2 (pt) * | 2008-11-10 | 2019-09-24 | Astute Medical Inc | método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal |
| CN105132395A (zh) | 2009-03-09 | 2015-12-09 | 生物蛋白有限公司 | Mirac蛋白 |
| JP5749255B2 (ja) | 2009-06-08 | 2015-07-15 | ユーシーエル ビジネス ピーエルシー | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
| BR112013000744A2 (pt) * | 2010-07-14 | 2020-07-14 | Cumberland Emerging Technologies, Inc | uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas |
| JP2012159356A (ja) * | 2011-01-31 | 2012-08-23 | Mochida Pharmaceut Co Ltd | 敗血症診断用組合せマーカー |
| CN103254295A (zh) * | 2013-05-31 | 2013-08-21 | 青岛国大生物制药股份有限公司 | 特利加压素的制备方法 |
| HRP20220225T1 (hr) * | 2014-10-24 | 2022-04-29 | Mallinckrodt Pharmaceuticals Ireland Limited | Terlipresin za liječenje hepatorenalnog sindroma tip 1 |
| JP2017014206A (ja) | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | 腹水の治療 |
-
2015
- 2015-10-22 HR HRP20220225TT patent/HRP20220225T1/hr unknown
- 2015-10-22 EP EP21208813.2A patent/EP3981420A1/en active Pending
- 2015-10-22 PT PT212057525T patent/PT3978074T/pt unknown
- 2015-10-22 FI FIEP21205752.5T patent/FI3978074T3/fi active
- 2015-10-22 ES ES21205752T patent/ES2987577T3/es active Active
- 2015-10-22 EP EP21205752.5A patent/EP3978074B1/en active Active
- 2015-10-22 PL PL21205752.5T patent/PL3978074T3/pl unknown
- 2015-10-22 PL PL15791430T patent/PL3209317T3/pl unknown
- 2015-10-22 HU HUE15791430A patent/HUE058066T2/hu unknown
- 2015-10-22 US US14/920,392 patent/US10335452B2/en active Active
- 2015-10-22 EP EP15791430.0A patent/EP3209317B1/en active Active
- 2015-10-22 DK DK15791430.0T patent/DK3209317T3/da active
- 2015-10-22 DK DK21205752.5T patent/DK3978074T3/da active
- 2015-10-22 SI SI201531790T patent/SI3209317T1/sl unknown
- 2015-10-22 PT PT157914300T patent/PT3209317T/pt unknown
- 2015-10-22 CN CN202111342532.XA patent/CN114028536B/zh active Active
- 2015-10-22 ES ES15791430T patent/ES2904492T3/es active Active
- 2015-10-22 CA CA2965325A patent/CA2965325A1/en not_active Abandoned
- 2015-10-22 CN CN201580062745.3A patent/CN107206049B/zh active Active
- 2015-10-22 WO PCT/US2015/056861 patent/WO2016065117A1/en not_active Ceased
- 2015-10-22 JP JP2017521988A patent/JP6673915B2/ja active Active
- 2015-10-22 AU AU2015335855A patent/AU2015335855A1/en not_active Abandoned
-
2019
- 2019-05-14 US US16/411,944 patent/US20190328831A1/en not_active Abandoned
- 2019-08-28 JP JP2019155678A patent/JP6989571B2/ja active Active
-
2021
- 2021-06-21 JP JP2021102221A patent/JP7346494B2/ja active Active
-
2022
- 2022-09-14 JP JP2022146052A patent/JP2022171795A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534618A5 (enExample) | ||
| Cairo et al. | Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation | |
| JP6989571B2 (ja) | １型肝腎症候群患者の治療方法 | |
| ES2716906T3 (es) | Métodos para reducir la tasa de exacerbación de asma mediante el uso de benralizumab | |
| JP2016516016A5 (enExample) | ||
| Gil et al. | Efficacy of hemocontrol biofeedback system in intradialytic hypotension-prone hemodialysis patients | |
| Calvaruso et al. | Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial | |
| Grünig et al. | Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial | |
| JP2023113870A (ja) | Ｂ因子阻害剤の使用方法 | |
| KR20220110727A (ko) | 고암모니아혈증의 치료를 위한 오르니틴 페닐아세테이트의 투여량 및 용도 | |
| Fedorak et al. | VSL3 probiotic mixture induces remission in patients with active ulcerative colitis | |
| JP2025519492A (ja) | 血友病ａ及びｂの処置のためのフィツシラン | |
| JP2006502231A5 (enExample) | ||
| Takaha et al. | Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer | |
| Jakacki et al. | Dose‐intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas | |
| Shimizu et al. | Long-term evaluation of partial splenic embolization followed by interferon therapy in patients with hepatitis C virus (HCV) cirrhosis and thrombocytopenia | |
| Sohn et al. | A case of acute eosinophilic myopericarditis presenting with cardiogenic shock and normal peripheral eosinophil count | |
| Kiskaddon et al. | Continuous intravenous sildenafil use, dose titration, tolerability and clinical outcomes in children with pulmonary hypertension. | |
| Yie et al. | A Case Report of Transfusion-related Acute Lung Injury (TRALI) Type II from A Heathy Male Donor | |
| Lee et al. | The Experience and Management of Two Cases of Metformin-associated Lactic Acidosis | |
| Glezerman | Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis | |
| Khalil et al. | Breakthrough Severe COVID-19 Infection After Triple Dose Pfizer Vaccination. | |
| Curry et al. | Benefit-to-risk profile in the label-specific population of patients with hepatorenal syndrome-acute kidney injury treated with terlipressin | |
| Michael et al. | Relationship of baseline weight and response to lumasiran in patients with primary hyperoxaluria type 1 on hemodialysis | |
| Lee et al. | A case of acute pulmonary thromboembolism after taking tadalafil |